Medical Editor: John P. Cunha, DO, FACOEP
What Is Zinacef?
Zinacef (cefuroxime) is a cephalosporin antibiotic used to treat a wide variety of bacterial infections. Zinacef may also be used before and during certain surgeries to help prevent infection.
What Are Side Effects of Zinacef?
Zinacef is available in generic form. Common side effects of Zinacef include:
- pain, or
- soreness at the injection site.
Zinacef may also infrequently cause:
- loss of appetite,
- irritability, or
Use of Zinacef for prolonged or repeated periods may result in oral thrush or a vaginal yeast infection. Tell your doctor if you have any serious side effects of Zinacef including:
- dark urine,
- easy bruising or bleeding,
- fast/pounding/irregular heartbeat,
- unusual weakness,
- yellowing eyes or skin, or
- mental/mood changes (such as confusion).
Dosage for Zinacef
The usual adult dosage range for Zinacef is 750 mg to 1.5 grams every 8 hours, usually for 5 to 10 days.
What Drugs, Substances, or Supplements Interact with Zinacef?
Zinacef may interact with other antibiotics, chloramphenicol, probenecid, “live” vaccines, or hormonal birth control. Tell your doctor all medications and supplements you use.
Zinacef During Pregnancy and Breastfeeding
Tell your doctor if you are pregnant before using Zinacef. This medication may decrease the effectiveness of hormonal birth control; consult your doctor. This medication passes into breast milk and may have undesirable effects on a nursing infant. Consult your doctor before breastfeeding.
Our Zinacef (cefuroxime) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
ZINACEF is generally well tolerated. The most common adverse effects have been local reactions following IV administration. Other adverse reactions have been encountered only rarely.
Thrombophlebitis has occurred with IV administration in 1 in 60 patients.
Gastrointestinal symptoms occurred in 1 in 150 patients and included diarrhea (1 in 220 patients) and nausea (1 in 440 patients). The onset of pseudomembranous colitis may occur during or after antibacterial treatment (see WARNINGS).
Hypersensitivity reactions have been reported in fewer than 1% of the patients treated with ZINACEF and include rash (1 in 125). Pruritus, urticaria, and positive Coombs' test each occurred in fewer than 1 in 250 patients, and, as with other cephalosporins, rare cases of anaphylaxis, drug fever, erythema multiforme, interstitial nephritis, toxic epidermal necrolysis, and Stevens-Johnson syndrome have occurred.
A decrease in hemoglobin and hematocrit has been observed in 1 in 10 patients and transient eosinophilia in 1 in 14 patients. Less common reactions seen were transient neutropenia (fewer than 1 in 100 patients) and leukopenia (1 in 750 patients). A similar pattern and incidence were seen with other cephalosporins used in controlled studies. As with other cephalosporins, there have been rare reports of thrombocytopenia.
Transient rise in SGOT and SGPT (1 in 25 patients), alkaline phosphatase (1 in 50 patients), LDH (1 in 75 patients), and bilirubin (1 in 500 patients) levels has been noted.
Elevations in serum creatinine and/or blood urea nitrogen and a decreased creatinine clearance have been observed, but their relationship to cefuroxime is unknown.
Postmarketing Experience With ZINACEF
In addition to the adverse events reported during clinical trials, the following events have been observed during clinical practice in patients treated with ZINACEF and were reported spontaneously. Data are generally insufficient to allow an estimate of incidence or to establish causation.
Immune System Disorders
Cutaneous vasculitis, angioedema, acute myocardial ischemia with or without myocardial infarction may occur as part of an allergic reaction.
Nervous System Disorders
Cephalosporin-Class Adverse Reactions
In addition to the adverse reactions listed above that have been observed in patients treated with cefuroxime, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibiotics:
Vomiting, abdominal pain, colitis, vaginitis including vaginal candidiasis, toxic nephropathy, hepatic dysfunction including cholestasis, aplastic anemia, hemolytic anemia, hemorrhage.
Several cephalosporins, including ZINACEF, have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced (see DOSAGE AND ADMINISTRATION). If seizures associated with drug therapy should occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.
Altered Laboratory Tests
Prolonged prothrombin time, pancytopenia, agranulocytosis.
To report SUSPECTED ADVERSE REACTIONS, contact Teligent Pharma, Inc. at 1-856697-1441, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Drug/Laboratory Test Interactions
A false-positive reaction for glucose in the urine may occur with copper reduction tests (Benedict's or Fehling's solution or with CLINITEST® tablets) but not with enzyme-based tests for glycosuria. As a false-negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase method be used to determine blood plasma glucose levels in patients receiving ZINACEF.
Cefuroxime does not interfere with the assay of serum and urine creatinine by the alkaline picrate method.
Read the entire FDA prescribing information for Zinacef (Cefuroxime)
© Zinacef Patient Information is supplied by Cerner Multum, Inc. and Zinacef Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.
Health Solutions From Our Sponsors